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oral candidiasis: a systematic review and
meta-analysis
Lijun Hu1, Mimi Zhou1, Andrew Young2, Weiwei Zhao1 and Zhimin Yan1*

Abstract
Background: To systematically review and assess the in vivo effectiveness and safety of probiotics for prophylaxis
and treating oral candidiasis.
Methods: A literature search for studies published in English until August 1, 2018 was conducted in the following
databases: PubMed, EMBASE, Cochrane Library, and Web of Science. Randomized controlled clinical trials and
experimental mouse animal model studies comparing probiotics (at any dosage and in any form) with control
groups (placebo, blank control or other agents) and reporting outcomes of the prophylactic and therapeutic effects
were considered for inclusion. A descriptive study and, potentially, a meta-analysis were planned.
Results: Six randomized controlled clinical trials and 5 controlled experiments of mouse animal models were
included in the systematic review. Four randomized controlled clinical trials comparing a probiotics group with a
placebo/blank control group in 480 elderly and denture wearers were included in the meta-analysis. The overall
combined odds ratio of the (random effects) meta-analysis was 0.24 (95% CI =0.09–0.63, P < 0.01). The overall
combined odds ratio of the (fixed effects) sensitivity analysis was 0.39 (95% CI =0.25–0.60, P < 0.01) by excluding a
study with the smallest sample size. These analyses showed that there was a statistically significant difference in the
effect of probiotics compared with the control groups in elderly and denture wearers. The remaining 2 studies
compared probiotics with other agents in a population aged 18–75 years and children aged 6–14 years respectively,
and were analyzed descriptively. Meta-analysis and descriptive analyses indicated that probiotics were potentially
effective in reducing morbidity, improving clinical symptoms and reducing oral Candida counts in oral candidiasis.
The biases of the included studies were low or uncertain. The relatively common complaints reported were
gastrointestinal discomfort and unpleasant taste, and no severe adverse events were reported.
Conclusions: Probiotics were superior to the placebo and blank control in preventing and treating oral candidiasis in
the elderly and denture wearers. Although probiotics showed a favorable effect in treating oral candidiasis, more
evidence is required to warrant their effectiveness when compared with conventional antifungal treatments.
Moreover, data on the safety of probiotics are still insufficient, and further research is needed.
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Background
Oral candidiasis (OC) is a fungal infection considered to
be the most common oral mucosal infectious disease [1]
and is mainly caused by Candida albicans. The detection rate of C. albicans in the general population is 20 to
75% [2–5]. It has also been reported that 15 to 71% of
denture wearers [3, 6, 7] and 80 to 95% of HIV-infected
individuals suffer from oral candidiasis [8–10]. The accepted treatment for oral candidiasis is the use of antifungal agents, such as nystatin, fluconazole, or miconazole.
[11]. Because of adverse effects and side effects, such as
the subsequent resistance of candida to antifungal agents,
dysgeusia, and gastrointestinal discomfort, including
nausea, vomiting and diarrhea, the clinical application
of antifungal drugs can be limited [12]. Therefore, the
exploration of new prophylaxis and therapeutic strategies for oral candidiasis is indicated.
Previous studies have reported that probiotics have effects on vulvovaginal candidiasis [13], dermatophytosis
[14], gastrointestinal infections [15], hypertension [16]
and colorectal cancer [17–19]. Known mechanisms of
probiotics include regulating innate and acquired immunity and releasing antioxidants and bacteriocins to
restore the balance of the microbial community and the
immune system [20–22]. Meanwhile, it is also reported
that probiotics are potentially promising treatment for
oral diseases such as periodontal disease, dental caries,
halitosis and oral candidiasis [23].
Over the last few years, probiotics have been demonstrated to enable the regulation of the oral microbiota
[24]. Studies have shown that Lactobacillus rhamnosus
[25], Lactobacillus reuteri [26], etc. can reduce oral
Candida counts. However, the estimated effects of probiotics in the treatment of oral candidiasis are conflicting [25–27]. Additionally, information on the safety of
probiotics is lacking. Therefore, the aim of this review is
to assess the effectiveness and safety of probiotics in the
prophylaxis and treatment of oral candidiasis using a
meta-analysis and systematic evaluation.

Methods
Data sources and search strategy

This systematic review was performed according to the
recommendations of the Preferred Reporting Items for
Systematic Reviews and Meta-analyses (PRISMA) [28].
Two of the authors (L.J. H and M.M. Z) independently
searched the following electronic databases: PubMed,
EMBASE, the Cochrane Library, and Web of Science for
articles published from inception to August 1, 2018. The
following terms were searched in combination: (“probiotics” OR “probiotic”) AND (“oral candidiasis” OR “oral
candidiases” OR “oral moniliasis” OR “oral moniliases”
OR “oral candida” OR “thrush”). Manual searches of the
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reference and citations of the identified studies were also
conducted as a supplement.
Study selection criteria

The inclusion criteria were as follows: (I) original studies; (II) randomized controlled clinical trials or experimental mouse animal model controlled studies; (III)
studies that compared probiotics (at any dosage and in
any form) with control groups (placebo, blank control or
other drugs); (IV) studies that reported specific outcomes of the therapeutic effect, such as the counts of
candida and/or clinical improvement; and (V) studies
published in the English language. Studies written in languages other than English, review articles, letters to the
editor, meeting summaries, patented inventions, unpublished articles and articles that did not have full-text
available were excluded.
Data extraction

The two investigators (L.J. H and M.M. Z) independently
identified the titles and abstracts that potentially met the
inclusion criteria. Then, full-text articles were read for a
complete assessment and determination of inclusion or
exclusion. Each investigator independently performed
the above steps. If the two review authors could not
reach a consensus regarding inclusion, a third reviewer
(Z.M. Y or A. Y) was invited to conduct an assessment
and settle any disagreements. For each included article,
data such as age, gender/sex, sample size, interventions,
follow-up time and outcome indicators were extracted
and summarized in a table format.
Risk of bias of the included studies

Three investigators (L.J. H, M.M. Z, and W.W. Z) evaluated the clinical studies based on the criteria of the
Cochrane handbook for systematic reviews of interventions using Review Manager 5.2 (Cochrane IMS, Oxford,
UK). The considered biases were as follows: (I) random
sequence generation (selection bias); (II) allocation concealment (selection bias); (III) blinding of participants
and personnel (performance bias); (IV) blinding of outcome assessment (detection bias); (V) incomplete outcome data (attrition bias); and (VI) selective reporting
(reporting bias).
For studies using animal models, the quality evaluation was based on the Collaborative Approach to
Meta Analysis and Review of Animal Data from
Experimental Studies (CAMARADES) [29]. The considered biases were as follows: (I) sample size calculation; (II) randomization of treatment or control;
(III) blinded assessment of outcome; (IV) allocation
concealment; (V) use of suitable animals; (VI) avoidance of anesthetics with marked intrinsic properties;
(VII) statement of control of temperature; (VIII)
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statement of compliance with regulatory requirements; (IX) publication in a peer-reviewed journal;
and (X) statement regarding possible conflicts of
interest.

Statistical analysis

Identification

Review Manager 5.2 was used to perform the metaanalyses. We assessed the therapeutic effect of probiotics
on oral candidiasis by means of odds ratios (ORs) and
their 95% confidence intervals (CIs) using MantelHaenszel statistics. Statistical heterogeneity analysis of
the included studies was performed using the I2 metric.
When I2 < 50%, the studies were considered to be sufficiently homogeneous, and a fixed effect model was used.
In contrast, when there was heterogeneity among the
studies, a random effects model was used, and sensitivity
analysis was conducted to achieve homogeneity among
the included studies.
For the smaller group of studies with poor homogeneity and for data provided by studies that could not be
analyzed by meta-analysis, descriptive analysis and
evaluation (i.e., qualitative analysis) was performed.

Results
Clinical research
Characteristics of the included studies

The number of included clinical studies was 6, which involved a total of 605 subjects (Fig. 1). The data extracted
from each study are summarized in Table 1.
Four of these studies, including 480 elderly and denture wearers, compared the effects of therapy between
the probiotics group and the blank or placebo group,
and a meta-analysis was performed [25–27, 30]. The
study by TY Miyazima et al. subdivided the probiotics
group into the T1 probiotics group using Lactobacillus
acidophilus NCFM and the T2 probiotics group using L.
rhamnosus Lr-32 [30]. Given the existing heterogeneity
of the interventions, this study combined the T1 probiotics group and T2 probiotics group as one group in the
meta-analysis.
Two of these studies were excluded in the metaanalysis and were evaluated by descriptive analysis due
to the comparison of probiotics with other agents. The
study by Duo Li et al. evaluated the short-term effectiveness and safety of probiotics in a population aged 18–75
years by comparing a probiotics group (received topical

Total (n=544)
Pubmed (n=185)
EMBASE (n=86)
Cochrane (n=63)
Web of science (n=210)

Screening

Duplicates found by the software
excluded (n=169)

Article abstracts and titles read
(n=375)

Included

Eligibility

Excluded
Irrelevant(n=311)
Letter, meeting abstract and patented
invention (n=10)
Review(n=19)

Fig. 1 Trial flow and study selection

Articles eligible for full-text screening
(n=35)

Articles eligible for this review (n=11)
Clinical trials (n=6)
Mouse animal model experiments (n=5)

Excluded
Full text unavailable (n=3)
Non-English language studies (n=1)
Non-mouse animal model experiments
(n=16)
Clinical trials with an unmatched
design (n=4)

8.65

Mishra et al.,
2016 [32]

3:17

61.7 ± 14.1

62.72 ± 9.57

66.1 ± 11.6

Miyazima et al.,
2017 [30]

Li et al., 2014 [31]

4:15

88.3 ± 5.7

Kraft-Bodi et al.,
2015 [26]

9:11

5:29

35:60

6:24

61.6 ± 7.8

Ishikawa et al.,
2015 [27]

36:100

58.7–95.2

20

34

20

19

84 (Baseline 95)

30

92 (Baseline 136)

Probiotics mint tablet
(unknown the types
of probiotics)

The combination of
B. longum, L. bulgaricus,
S. thermophiles, 2%
Sodium bicarbonate
solution and 2%
Nysfungin cataplasm

L. rhamnosus

L. acidophilus

L. reuteri

The combination of
L. rhamnosus HS111,
L. acidophilus HS101
and B. bifidum

The combination of
L. rhamnosus and
P. freudenreichii

11:9
12:8

9.70

7:24

3:17

42:61

8:17

30:110

Gender
(M:F)

8.90

64.84 ± 11.92

65.5 ± 10.5

87.7 ± 7.7

62.1 ± 9.4

65.4–94.7

Age
(Average)

Interventions

Control group
Sample size

Age
(Average)

Gender
(M:F)

Probiotics group

Hatakka et al.,
2007 [25]

Author and
publication
year

Table 1 Characteristics of the included clinical studies

20

20

31

20

90 (Baseline 103)

25

100 (Baseline 140)

Sample size

Herbal gargle

0.2% Chlorhexidine
digluconate

2% Sodium
bicarbonate
solution + 2%
Nysfungin cataplasm

Blank control

Placebo

Placebo

Blank control

Interventions

1

4

8

12

5

16

Follow-up
time (weeks)

Candida counts

Candida counts;
pain level;
hyperaemia

Candida counts

Candida counts;
oral hygiene;
gingival inflammation

Candida counts

Candida counts;
hyposalivation;
salivary buffering
capacity;
dry mouth;
mucosal lesions;
oral pain;
decayed teeth

Outcome indicators
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Table 2 Bias assessment of the included clinical studies
Author and
publication year

Random sequence Allocation
Blinding of participants Blinding of outcome Incomplete
Selective Other bias
generation
concealment and personnel
assessment
outcome data reporting

Hatakka et al., 2007 [25]

Low risk

Uncertain

Low risk

Uncertain

Low risk

Low risk

Uncertain

Ishikawa et al., 2015 [27]

Uncertain

Uncertain

Low risk

Low risk

Low risk

Low risk

Low risk

Kraft-Bodi et al., 2015 [26] Low risk

Low risk

Low risk

Low risk

Uncertain

Low risk

Low risk

Miyazima et al., 2017 [30]

Uncertain

Uncertain

Low risk

Uncertain

Low risk

Low risk

Low risk

Li et al., 2014 [31]

Low risk

Uncertain

High risk

High risk

Low risk

Low risk

Low risk

Mishra et al., 2016 [32]

Uncertain

Uncertain

Low risk

Uncertain

Low risk

Low risk

Uncertain

antifungal agents—sodium bicarbonate solution and nystatin—as well as Bifidobacterium longum, Lactobacillus
bulgaricus and Streptococcus thermophilus) with a control group (received only topical antifungal agents) [31].
The trial by Rahul Mishra et al. compared the antimicrobial effect of probiotics in children aged 6–14 years with
herbal rinse and commonly used antimicrobial agents of
0.2% chlorhexidine [32]. However, the types of probiotics
contained in the probiotic product were not mentioned
in the article.
Quality of the included studies

According to the Cochrane risk of bias assessment criteria, the included studies failed to achieve all seven aspects in detail. The quality evaluations of the studies are
listed in Table 2. The overall risk of each type of bias is
presented in Fig. 2, and the risk of each bias in each of
the included studies is presented in Fig. 3. The risk of
bias assessment for the included studies was conducted
by 2 independent researchers (L.J. H and M.M. Z), and
the consistency of the assessment results was 100%.
Effectiveness assessment

Meta-analysis was performed on 4 studies with a total of
480 subjects that compared a probiotics group with a
placebo or blank control group [25–27, 30]. The heterogeneity analysis of these 4 studies yielded x2 = 13.41,
P = 0.004, and I2 = 78%. The random effects model

analysis showed that there was a statistically significant difference in the effect of probiotics for preventing and treating oral candidiasis in elderly and denture
wearers compared with the control groups (OR = 0.24,
95% CI =0.09–0.63, P < 0.01; Fig. 4).
Sensitivity analysis was performed in the metaanalysis. After removing 1 study with the smallest sample size, the remaining 3 studies were of good homogeneity with an I2 value of 0% [27]. The fixed effect model
analysis showed that there was a statistically significant
difference in the effect of probiotics compared with the
control groups in elderly and denture wearers (OR =
0.39, 95% CI =0.25–0.60, P < 0.01; Fig. 5). Thus, taken
together, the meta-analysis indicated that probiotics may
be potentially effective for oral candidiasis in the elderly
and denture wearers.
In addition, two studies compared the effect of probiotics with other drugs, including the combination of nystatin paste and a sodium bicarbonate solution, Chinese
herbal rinse and 0.2% chlorhexidine digluconate rinse
[31, 32]. Although hyperemia of the probiotics group
using the combination of probiotics, nystatin paste and
sodium bicarbonate solution improved after 4 weeks of
follow-up, it did not show significant differences compared with the control group without probiotics.
However, the detection rate of Candida spp. in the
probiotics group (8.2%) was significantly lower than
in the control group (34.6%) in this population aged

Fig. 2 Risk of bias graph: the overall risk of each bias is presented as a percentage representing the risk in all the included studies
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was from the Chinese herbal rinse (P > 0.01) [32].
From the above information, probiotics exhibit the
potential effect of inhibiting the colonization of Candida on the surface of oral mucosa and improving
the clinical signs and symptoms of fungal infections.
Safety evaluation

Only 2 of the 6 studies included information about adverse events or complaints with probiotics [26, 31]. One
study reported that the probiotic had no adverse events
[31], while the other reported that its most common
complaints were an unpleasant taste and gastric discomfort, with incidences of 6 and 2.87%, respectively, but no
severe adverse events were reported [26].
Animal research

Fig. 3 Risk of bias summary: the risk of each bias in each of the
included studies is shown separately. Note: +,?, − indicate high,
uncertain, and low bias, respectively

18–75 years (P = 0.038) [31]. Therefore, probiotics
helped to improve the clinical symptoms of oral candidiasis and reduce the detection rate of Candida
spp. more than using antifungal drugs alone. The
0.2% chlorhexidine digluconate rinse group had the
best effects in terms of decreasing the number of C.
albicans colony-forming units (CFUs) per milliliter in
children aged 6–14 years (P < 0.01), followed by the
probiotics group (P < 0.01), and the poorest outcome

Through a literature search and screening, a total of
5 studies that met the criteria were included [33–37].
Table 3 lists the 5 studies and the data extracted,
which included publication date, sex, age and strain
of the mouse animal model, number of mice, method
of candida infection, probiotic species, method of
drug administration, intervention time, control group,
and outcome indicators. The bias assessment of the
included mouse animal model experiments is summarized in Table 4.
Because the original data of Candida colony-forming
units per milliliter and symptom score could not be obtained, a descriptive analysis was performed. First, compared with the blank group, L. acidophilus, L. rhamnosus
and 3 × 109 CFU/ml of Streptococcus salivarius K12 all
showed the effect of reducing the Candida counts (P <
0.05) [33–35, 37]. In 2 studies conducted by Sanae A. Ishijima et al., 1.5 × 109 CFU/ml and 3 × 109 CFU/ml of S. salivarius K12 and 15 mg/ml and 30 mg/ml of Enterococcus
faecalis all indicated an obviously significant difference
from the control group (P < 0.01) [34, 36]. Second, L.
rhamnosus could significantly reduce the Candida
counts compared with nystatin (P < 0.05) [33]. When
compared with fluconazole, a study reported that mice

Fig. 4 Odds ratio and 95% confidence intervals from individual studies. Forest plots evaluating the effect of probiotics (random-effect model).
Note: events indicate the subjects with oral candidiasis
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Fig. 5 Sensitivity test: forest plot of odds ratio and 95% confidence intervals in studies at low risk of bias (fixed-effect model). Note: events indicate the
subjects with oral candidiasis

given 15 mg/ml of E. faecalis had a significant decrease in
fungal burden, although this was not observed to be a
complete cure [36]. These results showed that probiotics
had an effect in reducing oral Candida counts and reducing the clinical signs and symptoms of fungal infections
in animal models.

Discussion
Attempting to treat oral candidiasis with probiotics has
gradually become a topic of considerable interest in research. The clinical studies and animal model experiments included in this review reported that probiotics
such as L. rhamnosus [25, 27, 30, 33, 37], Propionibacterium freudenreichii [25], L. acidophilus [27, 30, 33, 35], L.
reuteri [26], B. longum [31], Bifidobacterium bifidum
[27], L. bulgaricus [31], S. thermophiles [31], L. fermentum [35], S. salivarius K12 [34] and heat-killed E. faecalis [36] have the effect of inhibiting the excessive growth
of Candida. Although the results of studies that met the
eligibility criteria appear to demonstrate that probiotics
have potential antifungal effects, the types of probiotics
selected in these studies were different, and some studies
focused on single probiotics [26, 30], while others focused
on a combination of multiple probiotics [25, 27, 31]. For
example, the study by TY Miyazima et al. reported that
using L. acidophilus or L. rhamnosus alone could reduce
oral Candida counts [30], while the study by Hatakka et
al. showed that the combined use of L. rhamnosus and P.
freudenreichii can reduce the risk of high yeast counts by
75% [25]. Additionally, in 2015, Ishikawa et al. indicated
that the combination of probiotics containing L. rhamnosus, L. acidophilus and B. bifidum reduced the level of
Candida colonization in dentures [27]. Since the types
and concentrations of probiotics varied between the studies included in this review, we were unable to determine
which species of probiotics and what specific doses are
optimal for treating oral candidiasis. Meanwhile, research
still needs to be done on which combinations of probiotics
have better curative effects and how probiotics work synergistically. It is worth noting, however, that the types of

probiotics in these 5 clinical studies [25–27, 30, 31] and 3
mouse-model experiments [34, 35, 37] were from the genera Lactobacillus and Bifidobacterium.
Of the included studies, there were studies comparing
the effect of probiotics with conventional antifungal
treatments [31, 32]. Duo Li et al. reported that oral local
antifungal agents (2% sodium bicarbonate solution and
nystatin) plus local probiotics helped to improve certain
clinical conditions and reduce the detection rate of Candida spp. [31]. Moreover, a study in 2016 demonstrated
that probiotic rinse was equally effective as 0.2% chlorhexidine digluconate rinse in reducing C. albicans
counts after 1 week of intervention [32]. However, there
is still insufficient evidence to prove that probiotics can
completely replace antifungal agents in the treatment of
oral candidiasis.
Of the 6 RCTs included, 3 evaluated the prophylaxis effect of probiotics in susceptible populations [25, 26, 32].
In total, in 366 elderly people from sheltered housing units
and nursing homes, probiotics of L. rhamnosus, P.
freudenreichii and L. reuteri were effective in reducing
Candida counts [25, 26]. In 60 children with carious teeth
(a predisposing factor of oral Candida carriage [38]), the
prophylactic effect of probiotics on oral candidiasis was
revealed [32]. The possible prophylactic mechanisms included competition with pathogenic microorganisms for
nutrients and receptors [39, 40] and releasing external
metabolites and producing hydrogen peroxide (H2O2), antagonizing the excessive growth of Candida [41, 42].
Based on current clinical studies, it is indicated that the
prophylactic use of probiotics might potentially reduce the
mobility of oral candidiasis and thus decrease the economic burden of the disease.
In addition to commonly used probiotic species, an
animal experiment included in this review reported that
heat-killed E. faecalis had an immunostimulatory effect
in a murine model of oral candidiasis, which is beneficial
for the treatment of oral candidiasis [36]. Heat-treated E.
faecalis has been reported to have immunoenhancing effects that include increasing cell-mediated immunity,

Strain

DBA/2

ICR

DBA/2, BALB/c
(Test data not
published)

ICR

Wistar mice
(immunosuppressed by
intraperitoneal
injection with
dexamethasone
(65 mg/kg))

Author and
publication year

Matsubara et al.,
2012 [33]

Ishijima et al.,
2012 [34]

Elahi et al.,
2005 [35]

Ishijima et al.,
2014 [36]

Leao et al.,
2018 [37]

Male

Female

Male

Female

Male

Gender

11–12

6

6–8

6

6–8

Age
(week)

90

73

25

55

152

Sample
sizes

Candida cotton swab
was left for 80 min
under the tongue

Candida cotton swab
to wipe oral mucosa

Candida cotton swab
to wipe oral mucosa

L. rhamnosus

E. faecalis

The combination of
L. acidophilus and
L. fermentum

S. salivarius K12

The combination of
L. acidophilus and
L. rhamnosus

–

Candida cotton swab
to wipe oral mucosa

Probiotic species

Method of
candida infection

Table 3 Characteristics of the included animal model experiments

24 h, 3 h before
Candida inoculation,
3 h, 24 h, 27 h after
Candida inoculation
2 weeks before
Candida inoculation;
Probiotics intake when
Candida inoculation

100 μL suspension
(10 9 cells/mL)

Start 2 weeks before
Candida inoculation,
qd, 28d

24 h, 3 h before
Candida inoculation,
3 h, 24 h, 27 h after
Candida inoculation

Start 2 weeks before
Candida inoculation,
qd, 27d

Intervention time

0.05 ml suspension

0.2 ml suspension
(109 probiotics)

0.05 ml suspension

0.2 ml suspension
(109 probiotics)

Method of drug
administration

Blank control

Fluconazole

Blank control

Blank control

Fluconazole

Blank control

Nystatin

Blank control

Control group

Candida counts,
Inflammatory infiltrate
score, The cytokines levels
(TNF-α, IL-1β, IL-4, IL-6,
IL-10, IL-12, and INF-γ)

Candida counts, Oral
infection score, Histology

Candida counts,
IL-4, IL-12, IFN-γ, NO

Candida counts,
Oral infection score,
Histology

Candida counts

Outcome indicators
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Randomization
of treatment
or control
✓
✓
✓
✓
–

Sample-size
calculation

–

–

–

–

✓

Author and
publication
year

Matsubara et al., 2012 [33]

Ishijima et al., 2012 [34]

Elahi et al., 2005 [35]

Ishijima et al., 2014 [36]

Leao et al., 2018 [37]

–

–

–

–

–

Allocation
concealment

–

–

–

–

–

Blinded
assessment
of outcome

Table 4 Bias assessment of the included mouse animal model experiments

✓

✓

✓

✓

✓

Suitable animal
model

✓

✓

✓

✓

–

Avoidance of
anaesthetics with
marked intrinsic
properties

✓

✓

✓

✓

–

Statement of
control of
temperature

✓

✓

–

✓

✓

Statement of
compliance with
regulatory
requirements

✓

✓

✓

✓

✓

Publication in
peer-reviewed
journal

✓

✓

–

–

–

Statement regarding
possible conflict of
interest
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humoral immunity, monocyte/macrophage function, and
natural killer cell activity in nonsensitized mice [43]. In
2012, an animal study aimed at the lysed E. faecalis in
the murine model of allergic rhinitis suggested that E.
faecalis has an immunoregulatory activity [44]. In a pilot
study, living nonpathogenic E. faecalis was shown to be
beneficial for the treatment of asthma [45]. However, no
study has investigated the clinical effect of E. faecalis on
oral candidiasis. This might open up a new research direction for the study of probiotics.
With respect to safety, the adverse events of probiotics
reported in the in vivo studies included in this systematic review were gastrointestinal discomfort and unpleasant taste [26]. No severe adverse events were reported
from either the clinical trials or the animal studies. However, a report issued by the Agency for Healthcare Research and Quality (AHRQ) in 2011 concluded that
although the existing clinical trials do not indicate an increased risk, this does not necessarily confirm the safety
of probiotics in intervention studies with confidence
[46]. The theoretically possible side effects of probiotics
were systemic infections, deleterious metabolic activities,
excessive immune stimulation in susceptible individuals,
and gene transfer [47]. For instance, a study reported
that a newborn with an umbilical bulge developed sepsis
after a 10-day administration of Bifidobacterium breve
BBG01 [48]. In contrast, a study published in 2015 indicated that probiotics are generally safe for most populations based on the preponderance of the data from
clinical trials, animal studies, and in vitro studies [49]. In
another study, 80 children aged 3 months to 3 years old
with rotavirus diarrhea were divided into placebo and
treatment groups. The treatment group given commercial sachets of Bifidobacterium did not report adverse
events during or after treatment [50]. Moreover, Lactobacillus, Bifidobacterium, and Enterococcus have been
used as food additives for a long period of time [51]. It
has been demonstrated that the widespread use of beverages containing probiotics such as Lactobacillus and
Bifidobacterium can reduce the prevalence of oral candidiasis in healthy individuals [52]. Thus, the reports are
contradictory. Therefore, further research is still needed
to confirm the safety and to evaluate adverse events related to probiotics in healthy people or patients.
Although aimed at collecting the best evidence to date,
this review still had limitations. First, the inconsistency
of the evaluation criteria of the clinical effects among
studies might be a source of heterogeneity. The limited
number of trials and subjects was also a restriction.
More trials are needed to verify the results above. Second,
the standard for the prophylactic and therapeutic use of
probiotics has not been established, and the combination
of probiotics, dosages, dosing regimens, vehicles, adverse
reactions, biodynamics and cost-effectiveness of the
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probiotics also need to be determined. Furthermore, although probiotics are beneficial to humans, as a living biological agent, it is still necessary to consider biological
tolerance and whether probiotics are suitable for various
types of people, such as immunosuppressed patients, infants and pregnant women. Much still needs to be learned
about this new treatment for oral candidiasis.

Conclusions
It is concluded in this systematic review that probiotics
were significantly superior to the placebo and blank control in preventing and treating oral candidiasis both in
clinical trials of elderly and denture wearers and in animal experiments, including inhibiting the colonization
of Candida on the surface of oral mucosa and reducing
the clinical signs and symptoms of fungal infections.
However, although probiotics showed a favorable effect
in treating oral candidiasis, more evidence is required to
confirm their effectiveness when compared with conventional antifungal treatments. Moreover, although the
commonly reported adverse events of probiotics were
relatively mild, the evidence for safety is still insufficient,
and further research is needed.
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